Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PLYMOUTH MEETING, PA., SEPT. 03, 2026 (GLOBE NEWSWIRE) -- HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY) TODAY ANNOUNCED THAT IT WILL PRESENT ENCORE DATA FROM THE COMPANY'S INVESTIGATION OF EPX-100 (CLEMIZOLE HYDROCHLORIDE) AT THE 16TH EUROPEAN EPILEPSY CONGRESS BEING HELD FROM SEPTEMBER 5-9, IN ATHENS, GREECE.

HARMONY BIOSCIENCES ANNOUNCES POSTER PRESENTATIONS AT THE 16TH EUROPEAN EPILEPSY CONGRESS

PLYMOUTH MEETING, PA., AUG. 27, 2026 (GLOBE NEWSWIRE) -- HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY), TODAY ANNOUNCED THAT HARMONY'S MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE IN NEW YORK, N.Y., ON THURSDAY, SEPTEMBER 10, 2026, AT 10:20 A.M., E.T.

HARMONY BIOSCIENCES TO PARTICIPATE IN 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE

PLYMOUTH MEETING, PA., AUG. 06, 2026 (GLOBE NEWSWIRE) -- HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY), TODAY ANNOUNCED THAT HARMONY'S MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER VIRTUAL CNS SYMPOSIUM ON THURSDAY, AUGUST 13, 2026, AT 1:30 P.M. ET.

HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER VIRTUAL CNS SYMPOSIUM

WAKIX NET REVENUE GREW 30% YEAR OVER YEAR TO $261.3 MILLION FOR SECOND QUARTER 2026; ESTIMATED AVERAGE PATIENTS INCREASED 450 TO 8,950; REITERATES 2026 WAKIX NET REVENUE GUIDANCE OF $1.0 BILLION TO $1.04 BILLION PHASE 1 SAD DATA FOR BP-205 DEMONSTRATE FAVORABLE PK AND SAFETY/TOLERABILITY PROFILES; PHASE 1 MAD DATA EXPECTED IN Q4 2026 BP-205 IND OPEN IN US; INITIATING PHASE 1B STUDY IN SLEEP-DEPRIVED HEALTHY VOLUNTEERS IN Q3; DATA EXPECTED EARLY 2027 INITIATING PHASE 2 TRIALS FOR BP-205 IN MID-2027 TO EVALUATE MULTIPLE CNS INDICATIONS PITOLISANT GR NDA ACCEPTED IN JULY; TARGET PDUFA DATE APRIL 1, 2027 PITOLISANT HD ON TRACK FOR PHASE 3 TOPLINE DATA IN 2027 AND TARGET PDUFA DATE IN 2028 CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET PLYMOUTH MEETING, PA.

HARMONY BIOSCIENCES ANNOUNCES RECORD Q2 2026 REVENUE AND SHARES INITIAL CLINICAL DATA FOR ITS OREXIN-2 AGONIST BP-205 REINFORCING POTENTIAL BEST-IN-CLASS PROFILE

PLYMOUTH MEETING, PA., JULY 21, 2026 (GLOBE NEWSWIRE) -- HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY) TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON TUESDAY, AUGUST 4, 2026, BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS. HARMONY WILL HOST A CONFERENCE CALL AND WEBCAST ON AUGUST 4, 2026, AT 8:30 A.M. ET TO DISCUSS THE RESULTS.

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 4, 2026

PLYMOUTH MEETING, PA.--(BUSINESS WIRE)--HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY) TODAY ANNOUNCED PRELIMINARY, UNAUDITED SECOND QUARTER 2026 NET PRODUCT REVENUE FOR WAKIX (PITOLISANT) OF APPROXIMATELY $261 MILLION, REPRESENTING A NEW QUARTERLY REVENUE RECORD FOR THE COMPANY AND GROWTH OF 30% YEAR OVER YEAR AND 21% GROWTH FOR Q2 OVER Q1. THESE RESULTS UNDERSCORE CONTINUED STRONG DEMAND FOR WAKIX, DISCIPLINED COMMERCIAL EXECUTION ACROSS THE FRANCHISE AND SUSTAINED MOMENTUM THROUGH THE FI.

HARMONY BIOSCIENCES PREANNOUNCES RECORD QUARTERLY REVENUE FOR Q2 2026, REAFFIRMS FULL-YEAR 2026 REVENUE GUIDANCE, AND ANNOUNCES CFO TRANSITION

PLYMOUTH MEETING, PA.--(BUSINESS WIRE)--HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY), TODAY ANNOUNCED THAT SIX ABSTRACTS IN NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA HAVE BEEN ACCEPTED FOR POSTER PRESENTATION AT SLEEP 2026, THE 40TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES (APSS), WHICH WILL BE HELD JUNE 14  17 IN BALTIMORE, MD. THE POSTER PRESENTATION DETAILS ARE AS FOLLOWS: ABSTRACT TITLE POSTER PRESENTATION SESSION TREATMENT WITH PITOLISANT IN SUBGROUPS OF ADULTS WITH.

HARMONY BIOSCIENCES ANNOUNCES POSTER PRESENTATIONS AT 2026 SLEEP ANNUAL MEETING

PLYMOUTH MEETING, PA.--(BUSINESS WIRE)--HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY), TODAY ANNOUNCED THAT HARMONY'S MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES. GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE FIRESIDE CHAT: JUNE 9, 2026, AT 8:40 A.M. ET LOCATION: MIAMI, FL OPPENHEIMER CNS & NEURO-MUSCULAR SUMMIT FIRESIDE CHAT: JUNE 10, 2026, AT 3:25 P.M. ET LOCATION: MIAMI, FL A WEBCAST OF THE FIRESIDE CHATS WILL BE AVAILABLE ON THE INVESTOR.

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PLYMOUTH MEETING, PA.--(BUSINESS WIRE)--HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY) TODAY REPORTED Q1 2026 REVENUE OF $215.4 MILLION, DELIVERING 17% YEAROVERYEAR GROWTH FOR WAKIX. PERFORMANCE DURING THE QUARTER REFLECTED CONTINUED STRONG DEMAND, OFFSET BY MARKET ACCESS HEADWINDS OBSERVED EVERY Q1, WHICH WERE MORE PRONOUNCED THIS YEAR. THIS FOLLOWS THE STRONGEST THREE CONSECUTIVE QUARTERS IN FRANCHISE HISTORY, AND THE COMPANY REINFORCED 2026 FULL YEAR REVENUE GUIDANCE. THE COMPANY ALSO.

HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES

PLYMOUTH MEETING, PA.--(BUSINESS WIRE)--HARMONY BIOSCIENCES HOLDINGS, INC. (NASDAQ: HRMY) TODAY ANNOUNCED THAT IT WILL REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON THURSDAY, MAY 7, 2026, BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS. HARMONY WILL HOST A CONFERENCE CALL AND WEBCAST ON MAY 7, 2026, AT 8:30 A.M. ET TO DISCUSS THE RESULTS. TO PARTICIPATE IN THE CALL, PLEASE DIAL 800-274-8461 (DOMESTIC) OR 203-518-9814 (INTERNATIONAL OR ALTERNATE), AND REFERENCE PASSCODE HRMYQ126. IT IS RECOMMENDE.

Harmony Biosciences Holdings, Inc.

HRMY

Price

Financial Reports

No items found.

Press Releases

Harmony Biosciences Holdings, Inc.

HRMY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

HRMY